125-71-3

1、Dextromethorphan was first patented under U.S. Patent 2,676,177.
2、The U.S. Food and Drug Administration (FDA) approved dextromethorphan for over-the-counter sale as a cough suppressant in 1958.
3、During the 1960s and 1970s, dextromethorphan became available in an over-the-counter tablet form by the brand name Romilar.
4、In 1973, Romilar was taken off the shelves after a burst in sales due to frequent abuse, and was replaced by cough syrup in an attempt to cut down on abuse.
5、More recently (the early 1990s), gel capsule forms began reappearing in the form of Drixoral Cough Liquid Caps and later Robitussin CoughGels as well as several generic forms of that preparation.

This chemical is called Dextromethorphan, and its systematic name is 9-alpha,13-alpha,14-alpha-Morphinan, 3-methoxy-17-methyl-. With the molecular formula of C₁₈H₂₅NO, its classification codes are Antitussive; Antitussive agents; Central Nervous System Agents; Drug / Therapeutic Agent; Excitatory Amino Acid Agents; Excitatory amino acid antagonists; Human Data; Neurotransmitter Agents; Respiratory System Agents. The CAS registry number of this chemical is 125-71-3. Additionally, its product categories are Respiratory Drugs; Medical and Biological Chemical; API. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity

Other characteristics of the Dextromethorphan can be summarised as followings: (1)ACD/LogP: 4.11; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.12; (4)ACD/LogD (pH 7.4): 2.39; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 14.9; (7)ACD/KOC (pH 5.5): 4.22; (8)ACD/KOC (pH 7.4): 78.03; (9)#H bond acceptors: 2; (10)#H bond donors: 0; (11)#Freely Rotating Bonds: 1; (12)Polar Surface Area: 12.47 Å²; (13)Index of Refraction: 1.585; (14)Molar Refractivity: 81.76 cm³; (15)Molar Volume: 243.8 cm³; (16)Polarizability: 32.41×10^-24cm³; (17)Surface Tension: 44.9 dyne/cm; (18)Density: 1.11 g/cm³; (19)Flash Point: 116.2 °C; (20)Enthalpy of Vaporization: 64.5 kJ/mol; (21)Boiling Point: 394.9 °C at 760 mmHg; (22)Vapour Pressure: 1.92E-06 mmHg at 25°C.

Uses of this chemical: The Dextromethorphan could be used to produce the ent-(17X)-3-methoxy-17-methyl-morphinane-17-oxide. This reaction needs the reagents of methanol, water and hydrogen peroxide.

You can still convert the following datas into molecular structure: 
1.SMILES: O(c1ccc3c(c1)[C@@]24[C@@H]([C@H](N(CC2)C)C3)CCCC4)C
2.InChI: InChI=1/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1
3.InChIKey: MKXZASYAUGDDCJ-NJAFHUGGBD

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
child	TDLo	oral	16mg/kg (16mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: ATAXIA	Pediatric Emergency Care. Vol. 7, Pg. 163, 1991.
child	TDLo	oral	38mg/kg (38mg/kg)	SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Pediatric Emergency Care. Vol. 13, Pg. 214, 1997.
dog	LDLo	intravenous	22mg/kg (22mg/kg)		Chemical and Pharmaceutical Bulletin. Vol. 7, Pg. 372, 1959.
mouse	LD50	oral	210mg/kg (210mg/kg)		Journal of Pharmaceutical Sciences. Vol. 60, Pg. 1523, 1971.
mouse	LD50	subcutaneous	112mg/kg (112mg/kg)		Chemical and Pharmaceutical Bulletin. Vol. 7, Pg. 372, 1959.
rat	LD50	intravenous	16286ug/kg (16.286mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA	Arzneimittel-Forschung. Drug Research. Vol. 45, Pg. 1188, 1995.
rat	LD50	oral	116mg/kg (116mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA SKIN AND APPENDAGES (SKIN): HAIR: OTHER	Arzneimittel-Forschung. Drug Research. Vol. 45, Pg. 1188, 1995.